Table 1. Patients' characteristics in the CN-AML cohort according to the MAPKBP1 expression.
| Variable | MAPKBP1high, n=78 | MAPKBP1low, n=79 | P |
|---|---|---|---|
| Median age. y (range) | 48.50 (18-77) | 51 (16-73) | 0.256 |
| Female sex, no.(%) | 37 (47.4) | 36 (45.6) | 0.87 |
| FAB subtype, no. | |||
| M0 | 1 | 2 | 1 |
| M1 | 28 | 17 | 0.05 |
| M2 | 19 | 13 | 0.24 |
| M3 | 1 | 0 | 0.50 |
| M4 | 13 | 11 | 0.66 |
| M5 | 14 | 25 | 0.06 |
| M6 | 0 | 1 | 1 |
| Other | 2 | 10 | 0.03 |
| FLT3-ITD, no. | 50 | 16 | <0.001 |
| FLT3-TKD, no. | 10 | 10 | 1 |
| NPM1, no. | 46 | 36 | 0.11 |
| CEBPA, mutated, no. | |||
| Single | 4 | 4 | 1 |
| Double | 5 | 11 | 0.18 |
| N-RAS, mutated, no. | 4 | 9 | 0.25 |
| K-RAS, mutated, no. | 0 | 1 | 1 |
| IDH1, mutated, no. | 10 | 9 | 0.81 |
| IDH2, mutated, no. | 5 | 8 | 0.81 |
| ELN genetic group, no | |||
| Favorable | 19 | 40 | 0.001 |
| Intermediate-I | 68 | 54 | 0.19 |
| High ERG, no. | 51 | 27 | <0.001 |
| High BAALC, no. | 44 | 34 | 0.11 |
| High LEF1, no. | 33 | 45 | 0.35 |
| High MN1, no. | 42 | 36 | 0.34 |
| High WT1, no. | 54 | 24 | <0.001 |
| High DNMT3B, no. | 55 | 23 | <0.001 |
| High TCF4, no. | 54 | 24 | <0.001 |
CN-AML indicates cytogenetically normal acute myeloid leukemia; FAB, French-American-British classification; ITD, internal tandem duplication; ELN, European Leukemia Net; and TKD, tyrosine kinase domain.
High ERG, BAALC, LEF1, MN1, WT1, DNMT3B and TCF4 expression were defined as an expression level above the median of all samples, respectively.